The aim of this study was to evaluate the efficacy and tolerance of vinorelbine as a single agent in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Patients were treated with oral or intravenous vinorelbine according to the pluridisciplinary tumor board’s decision. Efficacy and safety outcomes were analyzed retrospectively. Twenty-three patients were included in the study. Sixteen patients (69%) had received at least two previous lines of chemotherapy. The disease control rate was 19%. The median progression-free survival was 2.6 months and the median overall survival was 3.4 months. The rate of grade 3–4 side effects was low (13%). Only one patient discontinued treatment because of side effects. Vinorelbine seems to be a well-tolerated regimen in heavily pretreated patients. However, this regimen does not seem to be efficient enough to be recommended.
Departments of aRadiation Oncology
bHead and Neck Surgery, Tenon Hospital, HUEP, UPMC, Paris VI University, Paris, France
Correspondence to Florence Huguet, MD, PhD, Radiation Oncology, Tenon Hospital, 4 rue de la Chine, 75020 Paris, France Tel: +33 1 56 01 83 22; fax: +33 1 56 01 64 00; e-mail: email@example.com
Received December 6, 2015
Accepted December 11, 2015